In prostate cancer, ST3Gal1 was shown to promote immune evasion by synthesizing α2,3‐sialylated ligands for Siglec‐7 and Siglec‐9 receptors on immunosuppressive macrophages, thereby disrupting anti‐tumor immunity.36 Here, ST3GAL1 is linked to prostate cancer.